nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrimeprazine—Necrotizing enterocolitis—Paclitaxel—ovarian cancer	0.0769	0.116	CcSEcCtD
Methotrimeprazine—Necrotising enterocolitis neonatal—Paclitaxel—ovarian cancer	0.0769	0.116	CcSEcCtD
Methotrimeprazine—Necrotising enterocolitis neonatal—Docetaxel—ovarian cancer	0.0651	0.0983	CcSEcCtD
Methotrimeprazine—Necrotizing enterocolitis—Docetaxel—ovarian cancer	0.0651	0.0983	CcSEcCtD
Methotrimeprazine—Necrotising colitis—Paclitaxel—ovarian cancer	0.0629	0.0948	CcSEcCtD
Methotrimeprazine—Necrotising colitis—Docetaxel—ovarian cancer	0.0533	0.0804	CcSEcCtD
Methotrimeprazine—Necrotising colitis—Epirubicin—ovarian cancer	0.0359	0.0542	CcSEcCtD
Methotrimeprazine—Necrotising colitis—Doxorubicin—ovarian cancer	0.0333	0.0502	CcSEcCtD
Methotrimeprazine—CHRM3—muscle of abdomen—ovarian cancer	0.0329	0.163	CbGeAlD
Methotrimeprazine—HTR2A—vein—ovarian cancer	0.0151	0.0746	CbGeAlD
Methotrimeprazine—Hepatocellular injury—Melphalan—ovarian cancer	0.0123	0.0186	CcSEcCtD
Methotrimeprazine—Drug interaction—Paclitaxel—ovarian cancer	0.00781	0.0118	CcSEcCtD
Methotrimeprazine—Jaundice—Chlorambucil—ovarian cancer	0.00771	0.0116	CcSEcCtD
Methotrimeprazine—Weight increased—Topotecan—ovarian cancer	0.00719	0.0108	CcSEcCtD
Methotrimeprazine—DRD4—testis—ovarian cancer	0.00712	0.0352	CbGeAlD
Methotrimeprazine—CHRM5—epithelium—ovarian cancer	0.00701	0.0347	CbGeAlD
Methotrimeprazine—Jaundice—Melphalan—ovarian cancer	0.00672	0.0101	CcSEcCtD
Methotrimeprazine—Drug interaction—Docetaxel—ovarian cancer	0.00662	0.00999	CcSEcCtD
Methotrimeprazine—ADRA1D—epithelium—ovarian cancer	0.00627	0.031	CbGeAlD
Methotrimeprazine—Hepatocellular injury—Docetaxel—ovarian cancer	0.00614	0.00926	CcSEcCtD
Methotrimeprazine—DRD5—female reproductive system—ovarian cancer	0.00581	0.0288	CbGeAlD
Methotrimeprazine—Agranulocytosis—Vinorelbine—ovarian cancer	0.00562	0.00848	CcSEcCtD
Methotrimeprazine—CHRM4—testis—ovarian cancer	0.00538	0.0266	CbGeAlD
Methotrimeprazine—DRD5—female gonad—ovarian cancer	0.00529	0.0262	CbGeAlD
Methotrimeprazine—Liver injury—Epirubicin—ovarian cancer	0.00492	0.00743	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Paclitaxel—ovarian cancer	0.0048	0.00725	CcSEcCtD
Methotrimeprazine—ADRA1D—female reproductive system—ovarian cancer	0.00466	0.0231	CbGeAlD
Methotrimeprazine—Liver injury—Doxorubicin—ovarian cancer	0.00456	0.00687	CcSEcCtD
Methotrimeprazine—ADRA2C—myometrium—ovarian cancer	0.00437	0.0216	CbGeAlD
Methotrimeprazine—Tachycardia—Melphalan—ovarian cancer	0.00429	0.00648	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Paclitaxel—ovarian cancer	0.00415	0.00626	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Epirubicin—ovarian cancer	0.00414	0.00625	CcSEcCtD
Methotrimeprazine—Weight increased—Paclitaxel—ovarian cancer	0.00414	0.00624	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Docetaxel—ovarian cancer	0.00407	0.00614	CcSEcCtD
Methotrimeprazine—Constipation—Topotecan—ovarian cancer	0.00384	0.0058	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Doxorubicin—ovarian cancer	0.00383	0.00578	CcSEcCtD
Methotrimeprazine—Tachycardia—Vinorelbine—ovarian cancer	0.00375	0.00566	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Chlorambucil—ovarian cancer	0.00372	0.00561	CcSEcCtD
Methotrimeprazine—ADRA1A—epithelium—ovarian cancer	0.0036	0.0178	CbGeAlD
Methotrimeprazine—HRH1—myometrium—ovarian cancer	0.00355	0.0176	CbGeAlD
Methotrimeprazine—Weight increased—Docetaxel—ovarian cancer	0.00351	0.00529	CcSEcCtD
Methotrimeprazine—ADRA2A—myometrium—ovarian cancer	0.00349	0.0173	CbGeAlD
Methotrimeprazine—HTR2C—female reproductive system—ovarian cancer	0.00345	0.0171	CbGeAlD
Methotrimeprazine—Photosensitivity—Epirubicin—ovarian cancer	0.00342	0.00517	CcSEcCtD
Methotrimeprazine—ADRA2C—uterine cervix—ovarian cancer	0.0034	0.0168	CbGeAlD
Methotrimeprazine—Jaundice—Docetaxel—ovarian cancer	0.00335	0.00505	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Topotecan—ovarian cancer	0.00331	0.00499	CcSEcCtD
Methotrimeprazine—Constipation—Vinorelbine—ovarian cancer	0.00329	0.00496	CcSEcCtD
Methotrimeprazine—CHRM1—female reproductive system—ovarian cancer	0.00326	0.0161	CbGeAlD
Methotrimeprazine—ADRA2C—decidua—ovarian cancer	0.00324	0.016	CbGeAlD
Methotrimeprazine—Hypersensitivity—Melphalan—ovarian cancer	0.00324	0.00489	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Docetaxel—ovarian cancer	0.00321	0.00484	CcSEcCtD
Methotrimeprazine—Photosensitivity—Doxorubicin—ovarian cancer	0.00317	0.00478	CcSEcCtD
Methotrimeprazine—ADRA2C—endometrium—ovarian cancer	0.00308	0.0152	CbGeAlD
Methotrimeprazine—CHRM3—female reproductive system—ovarian cancer	0.00291	0.0144	CbGeAlD
Methotrimeprazine—HTR2A—embryo—ovarian cancer	0.00285	0.0141	CbGeAlD
Methotrimeprazine—ADRA2C—uterus—ovarian cancer	0.00284	0.014	CbGeAlD
Methotrimeprazine—Hypersensitivity—Vinorelbine—ovarian cancer	0.00283	0.00427	CcSEcCtD
Methotrimeprazine—HRH1—epithelium—ovarian cancer	0.00279	0.0138	CbGeAlD
Methotrimeprazine—HRH1—uterine cervix—ovarian cancer	0.00276	0.0137	CbGeAlD
Methotrimeprazine—Orthostatic hypotension—Epirubicin—ovarian cancer	0.00275	0.00414	CcSEcCtD
Methotrimeprazine—ADRA2A—uterine cervix—ovarian cancer	0.00271	0.0134	CbGeAlD
Methotrimeprazine—CHRM3—female gonad—ovarian cancer	0.00265	0.0131	CbGeAlD
Methotrimeprazine—HRH1—decidua—ovarian cancer	0.00263	0.013	CbGeAlD
Methotrimeprazine—ADRA2A—decidua—ovarian cancer	0.00259	0.0128	CbGeAlD
Methotrimeprazine—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.00254	0.00383	CcSEcCtD
Methotrimeprazine—Tachycardia—Paclitaxel—ovarian cancer	0.00252	0.00381	CcSEcCtD
Methotrimeprazine—HRH1—endometrium—ovarian cancer	0.0025	0.0124	CbGeAlD
Methotrimeprazine—ADRA2A—endometrium—ovarian cancer	0.00246	0.0122	CbGeAlD
Methotrimeprazine—Photosensitivity reaction—Epirubicin—ovarian cancer	0.00237	0.00358	CcSEcCtD
Methotrimeprazine—Weight increased—Epirubicin—ovarian cancer	0.00237	0.00357	CcSEcCtD
Methotrimeprazine—CHRM3—testis—ovarian cancer	0.00235	0.0116	CbGeAlD
Methotrimeprazine—HTR2A—epithelium—ovarian cancer	0.00233	0.0115	CbGeAlD
Methotrimeprazine—ADRA2C—female gonad—ovarian cancer	0.00232	0.0115	CbGeAlD
Methotrimeprazine—Drowsiness—Epirubicin—ovarian cancer	0.00232	0.0035	CcSEcCtD
Methotrimeprazine—ADRA2C—vagina—ovarian cancer	0.00231	0.0114	CbGeAlD
Methotrimeprazine—Somnolence—Paclitaxel—ovarian cancer	0.0023	0.00347	CcSEcCtD
Methotrimeprazine—ADRA2A—gonad—ovarian cancer	0.00228	0.0113	CbGeAlD
Methotrimeprazine—ADRA2A—uterus—ovarian cancer	0.00226	0.0112	CbGeAlD
Methotrimeprazine—Jaundice—Epirubicin—ovarian cancer	0.00226	0.00341	CcSEcCtD
Methotrimeprazine—Constipation—Paclitaxel—ovarian cancer	0.00221	0.00333	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.0022	0.00331	CcSEcCtD
Methotrimeprazine—Weight increased—Doxorubicin—ovarian cancer	0.00219	0.0033	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Epirubicin—ovarian cancer	0.00216	0.00326	CcSEcCtD
Methotrimeprazine—Drowsiness—Doxorubicin—ovarian cancer	0.00214	0.00323	CcSEcCtD
Methotrimeprazine—Tachycardia—Docetaxel—ovarian cancer	0.00214	0.00323	CcSEcCtD
Methotrimeprazine—DRD2—testis—ovarian cancer	0.00212	0.0105	CbGeAlD
Methotrimeprazine—Jaundice—Doxorubicin—ovarian cancer	0.00209	0.00315	CcSEcCtD
Methotrimeprazine—HRH1—female reproductive system—ovarian cancer	0.00207	0.0103	CbGeAlD
Methotrimeprazine—ADRA2C—testis—ovarian cancer	0.00206	0.0102	CbGeAlD
Methotrimeprazine—ADRA2A—female reproductive system—ovarian cancer	0.00203	0.0101	CbGeAlD
Methotrimeprazine—Agranulocytosis—Doxorubicin—ovarian cancer	0.002	0.00302	CcSEcCtD
Methotrimeprazine—CYP2E1—female reproductive system—ovarian cancer	0.00199	0.00985	CbGeAlD
Methotrimeprazine—Somnolence—Docetaxel—ovarian cancer	0.00195	0.00294	CcSEcCtD
Methotrimeprazine—HTR2A—gonad—ovarian cancer	0.00194	0.00959	CbGeAlD
Methotrimeprazine—Hypersensitivity—Paclitaxel—ovarian cancer	0.0019	0.00287	CcSEcCtD
Methotrimeprazine—HRH1—female gonad—ovarian cancer	0.00188	0.00933	CbGeAlD
Methotrimeprazine—Constipation—Docetaxel—ovarian cancer	0.00187	0.00283	CcSEcCtD
Methotrimeprazine—HRH1—vagina—ovarian cancer	0.00187	0.00927	CbGeAlD
Methotrimeprazine—ADRA2A—female gonad—ovarian cancer	0.00185	0.00916	CbGeAlD
Methotrimeprazine—ADRA2A—vagina—ovarian cancer	0.00184	0.00911	CbGeAlD
Methotrimeprazine—HTR2A—female reproductive system—ovarian cancer	0.00173	0.00856	CbGeAlD
Methotrimeprazine—HRH1—testis—ovarian cancer	0.00167	0.00827	CbGeAlD
Methotrimeprazine—ADRA2A—testis—ovarian cancer	0.00164	0.00813	CbGeAlD
Methotrimeprazine—Hypersensitivity—Docetaxel—ovarian cancer	0.00161	0.00244	CcSEcCtD
Methotrimeprazine—CYP2E1—testis—ovarian cancer	0.00161	0.00795	CbGeAlD
Methotrimeprazine—CYP2D6—female reproductive system—ovarian cancer	0.00158	0.0078	CbGeAlD
Methotrimeprazine—HTR2A—vagina—ovarian cancer	0.00156	0.00774	CbGeAlD
Methotrimeprazine—ADRA2C—lymph node—ovarian cancer	0.00149	0.00738	CbGeAlD
Methotrimeprazine—Tachycardia—Epirubicin—ovarian cancer	0.00144	0.00218	CcSEcCtD
Methotrimeprazine—CYP2D6—female gonad—ovarian cancer	0.00143	0.0071	CbGeAlD
Methotrimeprazine—HTR2A—testis—ovarian cancer	0.0014	0.00691	CbGeAlD
Methotrimeprazine—Tachycardia—Doxorubicin—ovarian cancer	0.00133	0.00201	CcSEcCtD
Methotrimeprazine—Somnolence—Epirubicin—ovarian cancer	0.00131	0.00198	CcSEcCtD
Methotrimeprazine—CYP2D6—testis—ovarian cancer	0.00127	0.0063	CbGeAlD
Methotrimeprazine—Constipation—Epirubicin—ovarian cancer	0.00126	0.00191	CcSEcCtD
Methotrimeprazine—Somnolence—Doxorubicin—ovarian cancer	0.00122	0.00183	CcSEcCtD
Methotrimeprazine—HRH1—lymph node—ovarian cancer	0.00121	0.006	CbGeAlD
Methotrimeprazine—ADRA2A—lymph node—ovarian cancer	0.00119	0.00589	CbGeAlD
Methotrimeprazine—Constipation—Doxorubicin—ovarian cancer	0.00117	0.00176	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Epirubicin—ovarian cancer	0.00109	0.00164	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Doxorubicin—ovarian cancer	0.00101	0.00152	CcSEcCtD
Methotrimeprazine—Diltiazem—ABCB1—ovarian cancer	0.000354	0.157	CrCbGaD
Methotrimeprazine—Triflupromazine—ABCB1—ovarian cancer	0.000316	0.14	CrCbGaD
Methotrimeprazine—Fluphenazine—ABCB1—ovarian cancer	0.000243	0.108	CrCbGaD
Methotrimeprazine—Clomipramine—ABCB1—ovarian cancer	0.000222	0.0985	CrCbGaD
Methotrimeprazine—Chlorprothixene—ABCB1—ovarian cancer	0.000221	0.098	CrCbGaD
Methotrimeprazine—Trimipramine—ABCB1—ovarian cancer	0.000204	0.0906	CrCbGaD
Methotrimeprazine—Promethazine—ABCB1—ovarian cancer	0.000197	0.0872	CrCbGaD
Methotrimeprazine—Trifluoperazine—ABCB1—ovarian cancer	0.000194	0.0861	CrCbGaD
Methotrimeprazine—Chlorpromazine—ABCB1—ovarian cancer	0.000152	0.0675	CrCbGaD
Methotrimeprazine—Imipramine—ABCB1—ovarian cancer	0.000152	0.0672	CrCbGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	1.38e-05	0.000104	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CCND1—ovarian cancer	1.37e-05	0.000103	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—KRAS—ovarian cancer	1.37e-05	0.000103	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CCND1—ovarian cancer	1.37e-05	0.000103	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—STAT3—ovarian cancer	1.37e-05	0.000103	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—NRAS—ovarian cancer	1.37e-05	0.000103	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CCND1—ovarian cancer	1.36e-05	0.000103	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	1.36e-05	0.000103	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	1.36e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	1.36e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MMP9—ovarian cancer	1.36e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CTNNB1—ovarian cancer	1.36e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—TP53—ovarian cancer	1.36e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—KRAS—ovarian cancer	1.36e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—KRAS—ovarian cancer	1.36e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CTNNB1—ovarian cancer	1.35e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CCND1—ovarian cancer	1.35e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—PTEN—ovarian cancer	1.35e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	1.35e-05	0.000101	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	1.34e-05	0.000101	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	1.34e-05	0.000101	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CTNNB1—ovarian cancer	1.34e-05	0.000101	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—TP53—ovarian cancer	1.34e-05	0.000101	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MMP9—ovarian cancer	1.34e-05	0.000101	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	1.34e-05	0.000101	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	1.33e-05	0.0001	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MMP9—ovarian cancer	1.33e-05	0.0001	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	1.33e-05	0.0001	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MMP9—ovarian cancer	1.33e-05	0.0001	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—PTEN—ovarian cancer	1.33e-05	0.0001	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	1.33e-05	0.0001	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PTEN—ovarian cancer	1.33e-05	9.99e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—PTEN—ovarian cancer	1.33e-05	9.98e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MMP9—ovarian cancer	1.33e-05	9.98e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—PIK3CA—ovarian cancer	1.32e-05	9.97e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—MYC—ovarian cancer	1.32e-05	9.97e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CAV1—ovarian cancer	1.32e-05	9.96e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	1.32e-05	9.96e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—PTEN—ovarian cancer	1.32e-05	9.95e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—AKT1—ovarian cancer	1.32e-05	9.92e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—PTEN—ovarian cancer	1.32e-05	9.92e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	1.31e-05	9.88e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MMP9—ovarian cancer	1.31e-05	9.88e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	1.31e-05	9.86e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	1.31e-05	9.85e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	1.31e-05	9.84e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	1.31e-05	9.84e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—PTEN—ovarian cancer	1.3e-05	9.82e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	1.3e-05	9.8e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	1.3e-05	9.78e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—HRAS—ovarian cancer	1.3e-05	9.76e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	1.3e-05	9.76e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	1.3e-05	9.75e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	1.3e-05	9.75e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—AKT1—ovarian cancer	1.29e-05	9.74e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—AKT1—ovarian cancer	1.29e-05	9.71e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	1.29e-05	9.69e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—AKT1—ovarian cancer	1.29e-05	9.68e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL2—ovarian cancer	1.28e-05	9.67e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—TP53—ovarian cancer	1.28e-05	9.64e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—HRAS—ovarian cancer	1.28e-05	9.63e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	1.28e-05	9.62e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—AKT1—ovarian cancer	1.27e-05	9.58e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	1.27e-05	9.57e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MYC—ovarian cancer	1.27e-05	9.57e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	1.27e-05	9.56e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.26e-05	9.52e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	1.26e-05	9.5e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—PIK3CA—ovarian cancer	1.26e-05	9.45e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	1.25e-05	9.43e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	1.25e-05	9.42e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.25e-05	9.42e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—PIK3CA—ovarian cancer	1.25e-05	9.37e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	1.25e-05	9.37e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	1.24e-05	9.37e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—EGFR—ovarian cancer	1.24e-05	9.36e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—IL6—ovarian cancer	1.24e-05	9.34e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	1.24e-05	9.34e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MYC—ovarian cancer	1.24e-05	9.31e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—HRAS—ovarian cancer	1.23e-05	9.22e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—IL6—ovarian cancer	1.22e-05	9.22e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	1.22e-05	9.21e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—TP53—ovarian cancer	1.22e-05	9.19e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—VEGFA—ovarian cancer	1.22e-05	9.18e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MYC—ovarian cancer	1.22e-05	9.16e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	1.22e-05	9.15e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	1.21e-05	9.11e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	1.21e-05	9.11e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	1.21e-05	9.1e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—STAT3—ovarian cancer	1.21e-05	9.09e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.21e-05	9.07e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—NRAS—ovarian cancer	1.2e-05	9.07e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—TP53—ovarian cancer	1.2e-05	9.07e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—TP53—ovarian cancer	1.2e-05	9.07e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	1.2e-05	9.04e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—VEGFA—ovarian cancer	1.2e-05	9.02e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—VEGFA—ovarian cancer	1.19e-05	8.99e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	1.19e-05	8.97e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	1.19e-05	8.96e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—VEGFA—ovarian cancer	1.19e-05	8.96e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—STAT3—ovarian cancer	1.19e-05	8.95e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—STAT3—ovarian cancer	1.19e-05	8.93e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—NRAS—ovarian cancer	1.19e-05	8.92e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—NRAS—ovarian cancer	1.18e-05	8.91e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—STAT3—ovarian cancer	1.18e-05	8.9e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	1.18e-05	8.88e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—NRAS—ovarian cancer	1.18e-05	8.88e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—VEGFA—ovarian cancer	1.18e-05	8.87e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—STAT3—ovarian cancer	1.18e-05	8.87e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—NRAS—ovarian cancer	1.18e-05	8.85e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	1.18e-05	8.85e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—KRAS—ovarian cancer	1.17e-05	8.85e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—IL6—ovarian cancer	1.17e-05	8.83e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—HRAS—ovarian cancer	1.17e-05	8.79e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—STAT3—ovarian cancer	1.17e-05	8.78e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—NRAS—ovarian cancer	1.16e-05	8.76e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	1.16e-05	8.76e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	1.16e-05	8.74e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MAPK3—ovarian cancer	1.15e-05	8.69e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—HRAS—ovarian cancer	1.15e-05	8.67e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—HRAS—ovarian cancer	1.15e-05	8.67e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—AKT1—ovarian cancer	1.15e-05	8.62e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	1.14e-05	8.6e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	1.14e-05	8.55e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MAPK3—ovarian cancer	1.13e-05	8.53e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—AKT1—ovarian cancer	1.13e-05	8.5e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MAPK3—ovarian cancer	1.13e-05	8.5e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MAPK3—ovarian cancer	1.13e-05	8.47e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	1.12e-05	8.47e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	1.12e-05	8.46e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MYC—ovarian cancer	1.12e-05	8.45e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—IL6—ovarian cancer	1.12e-05	8.41e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MAPK3—ovarian cancer	1.11e-05	8.39e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	1.11e-05	8.37e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—PIK3CA—ovarian cancer	1.11e-05	8.37e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MYC—ovarian cancer	1.1e-05	8.31e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—IL6—ovarian cancer	1.1e-05	8.3e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—IL6—ovarian cancer	1.1e-05	8.3e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MYC—ovarian cancer	1.1e-05	8.3e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MYC—ovarian cancer	1.1e-05	8.27e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MAPK1—ovarian cancer	1.1e-05	8.27e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—EGFR—ovarian cancer	1.1e-05	8.26e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MYC—ovarian cancer	1.09e-05	8.24e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	1.09e-05	8.22e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.09e-05	8.21e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—TP53—ovarian cancer	1.09e-05	8.19e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MYC—ovarian cancer	1.08e-05	8.16e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—AKT1—ovarian cancer	1.08e-05	8.14e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MYC—ovarian cancer	1.08e-05	8.14e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	1.08e-05	8.14e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	1.08e-05	8.13e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—EGFR—ovarian cancer	1.08e-05	8.13e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	1.08e-05	8.13e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	1.08e-05	8.12e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MAPK1—ovarian cancer	1.08e-05	8.12e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—EGFR—ovarian cancer	1.08e-05	8.11e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MAPK1—ovarian cancer	1.07e-05	8.09e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—EGFR—ovarian cancer	1.07e-05	8.09e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MAPK1—ovarian cancer	1.07e-05	8.06e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—EGFR—ovarian cancer	1.07e-05	8.06e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MAPK1—ovarian cancer	1.06e-05	7.99e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—EGFR—ovarian cancer	1.06e-05	7.98e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.06e-05	7.98e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	1.06e-05	7.96e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	1.06e-05	7.96e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	1.05e-05	7.9e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—TP53—ovarian cancer	1.04e-05	7.86e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	1.04e-05	7.83e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—KRAS—ovarian cancer	1.04e-05	7.81e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	1.03e-05	7.78e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	1.03e-05	7.78e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—AKT1—ovarian cancer	1.03e-05	7.76e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—AKT1—ovarian cancer	1.03e-05	7.72e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—KRAS—ovarian cancer	1.02e-05	7.68e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—PIK3CA—ovarian cancer	1.02e-05	7.68e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—KRAS—ovarian cancer	1.02e-05	7.66e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—AKT1—ovarian cancer	1.02e-05	7.66e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—AKT1—ovarian cancer	1.02e-05	7.66e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—TP53—ovarian cancer	1.02e-05	7.65e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—KRAS—ovarian cancer	1.01e-05	7.64e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—KRAS—ovarian cancer	1.01e-05	7.62e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MYC—ovarian cancer	1e-05	7.56e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—KRAS—ovarian cancer	1e-05	7.54e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—TP53—ovarian cancer	1e-05	7.53e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	9.99e-06	7.52e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—HRAS—ovarian cancer	9.99e-06	7.52e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—IL6—ovarian cancer	9.95e-06	7.49e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	9.83e-06	7.4e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	9.83e-06	7.4e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	9.71e-06	7.31e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	9.56e-06	7.2e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—IL6—ovarian cancer	9.56e-06	7.2e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	9.53e-06	7.17e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PTEN—ovarian cancer	9.42e-06	7.09e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	9.37e-06	7.06e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PIK3CA—ovarian cancer	9.37e-06	7.05e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	9.35e-06	7.04e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—PIK3CA—ovarian cancer	9.32e-06	7.02e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—IL6—ovarian cancer	9.3e-06	7e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—PIK3CA—ovarian cancer	9.29e-06	7e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	9.28e-06	6.99e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	9.24e-06	6.95e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—TP53—ovarian cancer	9.22e-06	6.94e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—PIK3CA—ovarian cancer	9.2e-06	6.93e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	9.18e-06	6.91e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	9.18e-06	6.91e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—IL6—ovarian cancer	9.15e-06	6.89e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—AKT1—ovarian cancer	9.08e-06	6.84e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—TP53—ovarian cancer	9.07e-06	6.83e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—TP53—ovarian cancer	9.05e-06	6.81e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—TP53—ovarian cancer	9.02e-06	6.79e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—TP53—ovarian cancer	8.99e-06	6.77e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—TP53—ovarian cancer	8.9e-06	6.7e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—TP53—ovarian cancer	8.88e-06	6.68e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—AKT1—ovarian cancer	8.82e-06	6.64e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—HRAS—ovarian cancer	8.81e-06	6.64e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—HRAS—ovarian cancer	8.67e-06	6.53e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—HRAS—ovarian cancer	8.65e-06	6.52e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—HRAS—ovarian cancer	8.63e-06	6.49e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—HRAS—ovarian cancer	8.6e-06	6.47e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	8.58e-06	6.46e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	8.53e-06	6.42e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—HRAS—ovarian cancer	8.52e-06	6.41e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	8.49e-06	6.39e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	8.44e-06	6.36e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—IL6—ovarian cancer	8.44e-06	6.35e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—AKT1—ovarian cancer	8.33e-06	6.27e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—IL6—ovarian cancer	8.3e-06	6.25e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—IL6—ovarian cancer	8.28e-06	6.24e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—IL6—ovarian cancer	8.26e-06	6.22e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—TP53—ovarian cancer	8.25e-06	6.21e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—IL6—ovarian cancer	8.23e-06	6.2e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—IL6—ovarian cancer	8.15e-06	6.14e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—IL6—ovarian cancer	8.13e-06	6.12e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PTEN—ovarian cancer	7.98e-06	6.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	7.89e-06	5.94e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—AKT1—ovarian cancer	7.78e-06	5.86e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—AKT1—ovarian cancer	7.66e-06	5.77e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—AKT1—ovarian cancer	7.65e-06	5.76e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—AKT1—ovarian cancer	7.64e-06	5.75e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—AKT1—ovarian cancer	7.62e-06	5.73e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—AKT1—ovarian cancer	7.59e-06	5.72e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL6—ovarian cancer	7.55e-06	5.69e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—AKT1—ovarian cancer	7.52e-06	5.66e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	7.5e-06	5.64e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	6.97e-06	5.24e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	6.65e-06	5e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	5.63e-06	4.24e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—AKT1—ovarian cancer	5.43e-06	4.09e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—AKT1—ovarian cancer	4.6e-06	3.46e-05	CbGpPWpGaD
